Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 12 of 6351
-
Can a single injection restore sight in a rare genetic eye disease?
Cure OngoingThe objective of this study is to evaluate the safety, tolerability, and efficacy of subretinal injection of NGGT001 in patients with Bietti Crystalline Corneoretinal Dystrophy (BCD) and to recommend the optimal dosage for future clinical administration.
Phase 1/2 • Sponsor: NGGT (Suzhou) Biotechnology Co., Ltd. • Aim: Cure
Last updated Aug 14, 2026 00:00 UTC
-
One pill may halt sleeping sickness spread
Disease control Recruiting nowThis protocol describes both the epidemiological study which aims at assessing whether over a three-year period a zero prevalence can be achieved when implementing a screen \& treat approach with acoziborole, as well as a nested clinical study aimed at generating further evidence…
Phase 3 • Sponsor: Institute of Tropical Medicine, Belgium • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Personalized chemo dosing may boost leukemia remission in kids
Cure Recruiting nowAim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for high risk acute lymphoblastic leukemia in children and adolescents.
Phase 2 • Sponsor: Hee Young Ju • Aim: Cure
Last updated Jul 31, 2026 00:00 UTC
-
Massive TB vaccine trial could save millions
Vaccine OngoingThe study is a randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mtb vaccine when administered intramuscularly (IM) on a 0,1-month schedule to adolescents an…
Phase 3 • Sponsor: Gates Medical Research Institute • Aim: Vaccine
Last updated Aug 30, 2026 00:00 UTC
-
Can a One-Time gene injection ease the burden of wet AMD?
Disease control Recruiting nowThis is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD. Based on results from the phase 1 dose escalation study, the phase 2 expansion study will be conducted.
Phase 1/2 • Sponsor: Skyline Therapeutics (US) Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can engineered immune cells tackle resistant blood cancers?
Disease control Recruiting nowThe purpose of this phase I study is to determine whether MDC-CAR-BCMA001 (BCMA directed CAR T-cells) is safe and tolerable in the treatment of relapsed and refractory B-cell malignancies
Phase 1 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
A sound wave that could expose hidden pancreatic cancer?
Diagnosis By invitation onlyAdenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic cancer and its noninvasive precancerous lesions. The test involves ultrasound and an analysis of pancreatic juice. A neural …
Sponsor: Adenocyte, LLC • Aim: Diagnosis
Last updated Aug 08, 2026 00:03 UTC
-
Immunotherapy may let some cancer patients skip the knife
Cure Recruiting nowThis phase II study evaluates dostarlimab followed by a watch-and-wait strategy in patients with localized dMMR/MSI-H gastric or gastroesophageal junction (GEJ) adenocarcinoma. The study aims to determine whether surgery can be safely avoided in patients achieving a complete resp…
Phase 2 • Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group • Aim: Cure
Last updated Aug 28, 2026 00:00 UTC
-
Gene-Editing breakthrough: could a single dose stop a deadly heart condition?
Disease control Recruiting nowTo evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
Phase 3 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Gene therapy could replace risky transplants for kids with hurler syndrome
Disease control OngoingA multi-center randomized clinical trial to compare OTL-203 (gene therapy) with stem cell transplant (standard of care) in patients with MPS-IH (Hurler syndrome).
Phase 3 • Sponsor: Orchard Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Can a single radiation dose cure large liver tumors?
Cure Recruiting nowThe RESCUE trial is a prospective, single-arm clinical study to evaluate the efficacy and safety of ablative radioembolization using Yttrium-90. This treatment is being investigated as a potential curative approach, as well as a bridging or downstaging strategy for surgery, in pa…
Phase 2 • Sponsor: Seoul National University Hospital • Aim: Cure
Last updated Aug 22, 2026 00:00 UTC
-
CAR-T therapy challenges stem cell transplant as First-Line treatment for multiple myeloma
Disease control OngoingThe purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in…
Phase 3 • Sponsor: Stichting European Myeloma Network • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Can engineered immune cells tackle an incurable childhood brain tumor?
Cure Recruiting nowThe CARMIGO Trial is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and young adults aged 2-16 years with Diffuse Midline Glioma (DMG). The study will evaluate the feasibility of gen…
Phase 1 • Sponsor: University College, London • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
-
Can a smart drug outperform chemotherapy for a common breast cancer subtype?
Disease control OngoingThe aim of this study was to evaluate whether the progression-free survival of SHR-A1811 was superior to investigator-selected chemotherapy in patients with HER2-low recurrent/metastatic breast cancer. To evaluate whether SHR-A1811 is superior to investigator-selected chemotherap…
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Gene therapy aims to restore hearing in children born deaf
Cure Recruiting nowRegeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat pediatric and adult participants who have severe-to profound and profound hearing loss due to changes in the otoferlin gene. The purpose of thi…
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Cure
Last updated Aug 07, 2026 00:00 UTC
-
Gene therapy hope for babies with fatal muscle disease
Disease control OngoingThis is a clinical study to evaluate the safety and efficacy of gene therapy drug SKG0201 Injection in patients with spinal muscular atrophy Type 1 (SMA 1).
Sponsor: Kun Sun • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Gene therapy breakthrough offers hope for boys with rare brain disease
Disease control OngoingMPS II is a genetic disorder that affects boys. Boys with MPS II are missing a working enzyme known as iduronate-2-sulfatase (IDS) which is needed to break down long sugar chains in the body. When this enzyme is missing, these sugars build up to excess causing damage, and stop or…
Phase 1/2 • Sponsor: University of Manchester • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Spinal implant plus rehab aims to help paralyzed patients stand and walk
Cure CompletedInterventional prospective longitudinal on the evaluation of spinal cord stimulation (SCS) assisted by motor rehabilitation training for restoring motor function in patients with spinal cord injury (SCI). The investigators will enroll ten research participants with clinically inc…
Sponsor: IRCCS San Raffaele • Aim: Cure
Last updated Aug 28, 2026 00:00 UTC
-
Could one drug replace the standard triple therapy for rectal cancer?
Disease control OngoingThe purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment. Participants who achieve complete clinical respon…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Supercharged immune cells take on advanced melanoma in major new trial
Disease control Recruiting nowThis is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Partici…
Phase 3 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC